Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2017

Open Access 01-12-2017 | Research article

Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine

Authors: Wei-Cheng Yang, Ching-Hua Lin, Fu-Chiang Wang, Mei-Jou Lu

Published in: BMC Psychiatry | Issue 1/2017

Login to get access

Abstract

Background

The aim of this study was to explore the relationships between depressive symptoms and health-related quality of life (HRQOL) measurements for inpatients with major depressive disorder (MDD) before and after 6-week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes.

Methods

A total of 131 inpatients with MDD were enrolled to receive 20 mg of fluoxetine for 6 weeks. Symptom severity and adverse events were assessed at weeks 0, 1, 2, 3, 4, and 6 using the 17-item Hamilton Depression Rating Scale (HAMD-17) and UKU Side Effect Rating Scale, respectively. HRQOL was measured using the Short Form 36 (SF-36), including 8 subscales, physical component summary (PCS) and mental component summary (MCS), at baseline and week 6. Spearman’s coefficient, Cohen’s d, and multiple linear regression model were used for statistical analysis.

Results

One hundred and six patients completing all measures at weeks 0 and 6 entered the analysis. HAMD-17 negatively correlated with SF-36 at baseline and week 6. The HAMD-17 had a larger effect size than SF-36. MCS, rather than PCS, showed statistically significant improvement. After using multiple linear regression analysis, age at onset, HAMD-17 score change, and number of adverse events reported during the trial period were related to MCS change after adjusting for confounding variables.

Conclusions

Fluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL. Depressive symptoms had a greater extent of change than HRQOL. Clinicians must consider the negative effects of adverse events caused by antidepressants on the improvement of HRQOL.

Trial registration

http://​clinicaltrials.​gov, NCT01075529, retrospectively registered 24/2/2010.
Literature
1.
Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med. 1995;41(10):1383–94.CrossRefPubMed
2.
Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157(5):669–82.CrossRefPubMed
3.
Patrick DL, Erickson P. What constitutes quality of life? Concepts and dimensions. Clin Nutr. 1988;7:53–63.
4.
Patten SB, Kennedy SH, Lam RW, O'Donovan C, Filteau MJ, Parikh SV, Ravindran AV. Canadian Network for M, Anxiety T: Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. Journal of affective disorders. 2009;117(Suppl 1):S5–14.CrossRefPubMed
5.
ten Doesschate MC, Koeter MW, Bockting CL, Schene AH, Group DS. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010;120(1–3):126–32.CrossRefPubMed
6.
Katschnig H, Freeman HL, Sartorius N. Quality of life in mental disorders, 2nd ed. Edn. Chichester: Wiley; 2006.
7.
De Fruyt J, Demyttenaere K. Quality of life measurement in antidepressant trials. Is there an added value? Psychother Psychosom. 2009;78(4):212–9.CrossRefPubMed
8.
Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162(6):1171–8.CrossRefPubMed
9.
Wisniewski SR, Rush AJ, Bryan C, Shelton R, Trivedi MH, Marcus S, Husain MM, Hollon SD, Fava M, Investigators SD. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007;195(3):219–25.CrossRefPubMed
10.
Souetre E, Martin P, Lozet H, Monteban H. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol. 1996;11(1):45–52.CrossRefPubMed
11.
Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, Van Rhoads RS, Reus VI, Raymond DePaulo Jr M J, Fawcett JA. Practice guideline for the treatment of patients with major depressive disorder third edition. Am J Psychiatry. 2010;167(10):1–152.
12.
Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011;31(2):187–93.CrossRefPubMed
13.
APA: American Psychiatric Association: Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1994.
14.
15.
Guy W: ECDEU Assessment manual for psychopharmacology. Washington DC: DHEW Publication 76338; 1976.
16.
Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91.CrossRefPubMed
17.
Schatzberg AF, Nemeroff CB. Essentials of clinical psychopharmacology. Washington, DC: American Psychiatric Pub; 2001.
18.
Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100.CrossRefPubMed
19.
Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis. J Psychiatr Res. 2009;43(8):792–7.CrossRefPubMed
20.
Harrison CL, Ferrier N, Young AH. Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol. 2004;18(2):200–4.CrossRefPubMed
21.
Daly EJ, Trivedi MH, Fava M, Shelton R, Wisniewski SR, Morris DW, Stegman D, Preskorn SH, Rush AJ. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol. 2011;31(1):31–8.CrossRefPubMed
22.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed
23.
Ware J.E. KM, Keller S.D. : SF-36 physical and mental health summary scales: a User's manual. Boston,MA: The Health Institute; 1994.
24.
Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10(5):405–13. discussion 415-420CrossRefPubMed
25.
Tseng HM, Lu JF, Tsai YJ. Assessment of health-relate quality of life: II. Norming and validation of SF-36 Taiwan version. Taiwan Journal of Public Helth. 2003;22(2):512–8.
26.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
27.
Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7(1):105–25.CrossRefPubMed
28.
Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton depression rating scale. J Psychiatr Res. 2000;34(1):3–10.CrossRefPubMed
29.
Forthofer RN, Lee ES, Hernandez M. Biostatistics : a guide to design, analysis, and discovery, 2nd ed. Edn. Amsterdam. London: Elsevier Academic Press; 2007.
30.
IsHak WW, Greenberg JM, Balayan K, Kapitanski N, Jeffrey J, Fathy H, Fakhry H, Rapaport MH. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011;19(5):229–39.CrossRefPubMed
31.
Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care - a randomized trial. Jama-Journal of the American Medical Association. 2001;286(23):2947–55.CrossRef
32.
Mann R, Gilbody S, Richards D. Putting the 'Q' in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009;44(7):569–78.CrossRefPubMed
33.
Enns MW, Larsen DK, Cox BJ. Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables. J Affect Disord. 2000;60(1):33–41.CrossRefPubMed
34.
Moller HJ. Rating depressed patients: observer- vs self-assessment. Eur Psychiatry. 2000;15(3):160–72.CrossRefPubMed
35.
Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan P, Keller M. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry Res. 2010;177(1–2):177–83.CrossRefPubMedPubMedCentral
36.
Moller HJ, von Zerssen D. Self-rating procedures in the evaluation of antidepressants. Psychopathology. 1995;28(6):291–306.CrossRefPubMed
37.
Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005;52(5):1577–84.CrossRefPubMed
38.
Hotopf M, Mayou R, Wadsworth M, Wessely S. Temporal relationships between physical symptoms and psychiatric disorder. Results from a national birth cohort. The British journal of psychiatry : the journal of mental science. 1998;173:255–61.CrossRef
39.
Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl. 1996;30:101–8.
40.
41.
Hung CI, Wang SJ, Liu CY. Validation of the depression and somatic symptoms scale by comparison with the short form 36 scale among psychiatric outpatients with major depressive disorder. Depress Anxiety. 2009;26(6):583–91.CrossRefPubMed
42.
Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286(23):2947–55.CrossRefPubMed
43.
Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2004;7(3):283–90.CrossRef
44.
Cao Y, Li W, Shen J, Malison RT, Zhang Y, Luo X. Health-related quality of life and symptom severity in Chinese patients with major depressive disorder. Asia Pac Psychiatry. 2013;5(4):276–83.CrossRefPubMed
45.
Kohler S, Unger T, Hoffmann S, Mackert A, Ross B, Fydrich T. The relationship of health-related quality of life and treatment outcome during inpatient treatment of depression. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2015;24(3):641–9.CrossRef
46.
Howard KI, Lueger RJ, Maling MS, Martinovich Z. A phase model of psychotherapy outcome: causal mediation of change. J Consult Clin Psychol. 1993;61(4):678–85.CrossRefPubMed
47.
McCall WV, Rosenquist PB, Kimball J, Haskett R, Isenberg K, Prudic J, Lasater B, Sackeim HA. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. The journal of ECT. 2011;27(2):97–102.CrossRefPubMed
48.
Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004;26(1):13–7.CrossRefPubMed
49.
Reed C, Monz BU, Perahia DGS, Gandhi P, Bauer M, Dantchev N, Demyttenaere K, Garcia-Cebrian A, Grassi L, Quail D, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009;113(3):296–302.CrossRefPubMed
50.
Diehr PH, Derleth AM, McKenna SP, Martin ML, Bushnell DM, Simon G, Patrick DL. Synchrony of change in depressive symptoms, health status, and quality of life in persons with clinical depression. Health Qual Life Outcomes. 2006;4:27.CrossRefPubMedPubMedCentral
51.
McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–63.CrossRefPubMed
52.
Moses T, Leuchter AF, Cook I, Abrams M. Does the clinical course of depression determine improvement in symptoms and quality of life? J Nerv Ment Dis. 2006;194(4):241–8.CrossRefPubMed
53.
Kaufman J, Martin A, King RA, Charney D. Are child-, adolescent-, and adult-onset depression one and the same disorder? Biol Psychiatry. 2001;49(12):980–1001.CrossRefPubMed
54.
Zisook S, Lesser I, Stewart JW, Wisniewski SR, Balasubramani GK, Fava M, Gilmer WS, Dresselhaus TR, Thase ME, Nierenberg AA, et al. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry. 2007;164(10):1539–46.CrossRefPubMed
55.
Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Thase ME, Rush AJ, et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord. 1999;55(2–3):149–57.CrossRefPubMed
56.
Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. The Journal of clinical psychiatry. 1998;59(11):608–19.CrossRefPubMed
57.
Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? The Journal of clinical psychiatry. 2004;65(4):521–30.CrossRefPubMed
58.
Berlim MT, McGirr A, Fleck MP. Can sociodemographic and clinical variables predict the quality of life of outpatients with major depression? Psychiatry Res. 2008;160(3):364–71.CrossRefPubMed
59.
Barge-Schaapveld DQ, Nicolson NA. Effects of antidepressant treatment on the quality of daily life: an experience sampling study. The Journal of clinical psychiatry. 2002;63(6):477–85.CrossRefPubMed
60.
Cheung AH, Levitt AJ, Szalai JP. Impact of antidepressant side effects on adolescent quality of life. Can J Psychiatry. 2003;48(11):727–33.CrossRefPubMed
61.
Beasley CM Jr, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. The Journal of clinical psychiatry. 2000;61(10):722–8.CrossRefPubMed
62.
Uzun S, Kozumplik O. Management of side effects of antidepressants - brief review of recommendations from guidelines for treatment of major depressive disorder. Psychiatr Danub. 2009;21(1):91–4.PubMed
63.
Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840–7.CrossRefPubMed
64.
Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22(1):40–5.CrossRefPubMed
65.
Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.CrossRefPubMedPubMedCentral
Metadata
Title
Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine
Authors
Wei-Cheng Yang
Ching-Hua Lin
Fu-Chiang Wang
Mei-Jou Lu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2017
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-017-1471-3

Other articles of this Issue 1/2017

BMC Psychiatry 1/2017 Go to the issue

Research article

The facial expression of schizophrenic patients applied with infrared thermal facial image sequence

Research article

Community-based psychosocial interventions for people with schizophrenia in low and middle-income countries: systematic review and meta-analysis

Research article

Contours of a causal feedback mechanism between adaptive personality and psychosocial function in patients with personality disorders: a secondary analysis from a randomized clinical trial

Research article

How effective is the comprehensive approach to rehabilitation (CARe) methodology? A cluster randomized controlled trial

Study protocol

The influence of participation in target-shooting sport for children with inattentive, hyperactive and impulsive symptoms – A controlled study of best practice

Research article

Methylphenidate use and school performance among primary school children: a descriptive study